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Abstract.
Background: Recent studies indicate that gene expression levels in blood may be able to differentiate subjects with Alzheimer’s
disease (AD) from normal elderly controls and mild cognitively impaired (MCI) subjects. However, there is limited replicability
at the single marker level. A pathway-based interpretation of gene expression may prove more robust.
Objectives: This study aimed to investigate whether a case/control classification model built on pathway level data was more
robust than a gene level model and may consequently perform better in test data. The study used two batches of gene expression
data from the AddNeuroMed (ANM) and Dementia Case Registry (DCR) cohorts.
Methods:Our study used Illumina Human HT-12 Expression BeadChips to collect gene expression from blood samples. Random
forest modeling with recursive feature elimination was used to predict case/control status. Age and APOE 4 status were used
as covariates for all analysis.
Results: Gene and pathway level models performed similarly to each other and to a model based on demographic
information only.
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Conclusions: Any potential increase in concordance from the novel pathway level approach used here has not lead to a greater
predictive ability in these datasets. However, we have only tested one method for creating pathway level scores. Further, we have
been able to benchmark pathways against genes in datasets that had been extensively harmonized. Further work should focus
on the use of alternative methods for creating pathway level scores, in particular those that incorporate pathway topology, and
the use of an endophenotype based approach.
Keywords: Alzheimer’s disease, blood, gene expression, pathways
INTRODUCTION
The most common form of dementia is Alzheimer’s
disease (AD). It is predicted that by 2050, 1 in every 85
people will be living with the disease [1]. No disease
modifying treatments are available for AD and exist-
ing treatments only provide short-term symptomatic
relief in a subset of patients [2]. Additionally, in the
early stages (between 2 and 15 years prior to the devel-
opment of clinical symptoms) the disease is difficult
to diagnose. Villemagne et al. and Jack et al. hypoth-
esize that characteristic AD pathology (the presence
of amyloid- (A) plaques and hyperphosphorylated
tau tangles in the brain) begins to develop up to 20
years prior to clinical diagnosis [3, 4]. This extended
prodromal stage is an important window in which to
target treatments that may be able to alter the course of
the disease; provided people could be sensitively and
accurately diagnosed. A, tau, and phosphorylated-tau
levels are indicative of AD pathology in this prodro-
mal period and can be measured in cerebrospinal fluid
(CSF) and by positron emission tomography (PET)
imaging [5]. The procedures involved in attaining these
measurements can be invasive or expensive and require
specialized administration, equipment. and expertise.
The development of a less invasive, potentially cheaper
technique, such as a blood test, would offer significant
advantages [6].
Recent studies indicate that gene expression levels
in blood may be able to differentiate AD subjects from
normal elderly controls and mild cognitive impairment
(MCI) subjects with prodromal disease [7–10]. Han
et al. provide an overview of studies of gene expres-
sion associated with AD-related phenotypes [11]. They
state that the blood transcriptome is vital in the disease
mechanism of AD and should therefore be investigated
further in independent studies of a large sample size.
A more general summary of gene expression data in
neurodegenerative diseases is given by Cooper-Knock
et al. [12]. This review emphasizes the dysregula-
tion in neuroinflammation and intracellular signaling
pathways including calcium signaling in AD. The
commonality between these reviews is that they both
highlight limited replicability at the single marker
level. Furthermore, Han et al. report a greater con-
cordance between differentially expressed genes at the
pathway level. A pathway-based interpretation of gene
expression may therefore prove more robust across dif-
ferent sample populations. Such an approach may also
reduce noise and dimensionality. It is important to note
that differential gene expression, as described in these
reviews, does not necessarily identify genes that will
be useful in a classification context.
Although previous gene expression studies in AD
have retrospectively identified pathways altered in dis-
ease [9], this is the first study to use pathway scores for
each individual to build predictive models across the
population. This study used Pathway Level Analysis of
Gene Expression (PLAGE) to estimate pathway vari-
ability across samples in the population by calculating
sample-wise pathway scores [14]. PLAGE outper-
formed other single sample enrichment methods such
as ZSCORE, Gene Set Variation Analysis (GSVA),
and Single Sample Gene Set Enrichment Analysis
(SSGSEA) in a comparison of sensitivity, specificity,
and prioritization by Tarca et al. [15]. PLAGE scores
have been used in univariate t-testing and unsuper-
vised clustering methods to investigate the pathways
involved in oral leukoplakia and those leading to cell
proliferation and migration in leukemia [16, 17]. We
combine, for the first time, PLAGE scoring with a
supervised machine learning approach to build an AD
classifier.
This study used blood expression data from sub-
jects participating in the AddNeuroMed (ANM) and
Dementia Case Registry (DCR) studies to develop
models of clinical diagnosis. The performance met-
rics of gene expression and demographic models is
compared with those generated using pathway level
measures of expression.
MATERIALS AND METHODS
Cohort
ANM is a European multi-center study aiming to
develop biomarkers for AD [18]. Subjects with an AD
diagnosis as well as those with MCI and healthy con-
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Fig. 1. Overview of sample numbers in batch 1 and 2 gene expression.
trols were recruited from centers based in Kuopio,
Lodz, London, Perugia, Thessaloniki, and Toulouse.
Details of study design and enrollment are provided
by Lunnon et al. [10]. Subjects for the DCR were
recruited from the Maudsley and Kings Healthcare
Partners, which incorporates the Alzheimer’s Research
UK (ARUK) cohort [19] from whom gene expression
data has not previously been reported.
The present study used data from 748 subjects: 614
subjects from ANM and 134 subjects from DCR.
Gene expression
Whole blood samples (2.5 ml) were collected after
2 h of fasting into Paxgene Blood RNA tubes (BD)
and extracted as in Lunnon et al. [9]. Illumina Human
HT-12 Expression BeadChips were used to analyze
the whole transcriptome according to the manufactur-
ers protocol. The gene expression analysis was run in
two batches at two different sites. Batch 1 contained
samples from 356 ANM subjects run on version 3 of
the BeadChip, as previously described [9, 10]. Batch 2
contained samples from 411 subjects: 134 from DCR
and 277 from ANM run on version 4 of the Bead-
Chip. Samples from 19 subjects were included in both
batches. See Fig. 1 for an overview of sample numbers.
The raw gene expression data are available as GEO
DataSets (Accession number GSE63060 for batch 1
and GSE63061 for batch 2).
Statistical analysis
Data pre-processing
The data pre-processing performed in this study is
different to that used for the original analysis by Lun-
non et al. [9, 10]. The data processing pipeline used
in this study aims to address the effects of technical
data artifacts in gene expression studies [20]. Raw gene
expression data was exported from Illumina’s Genome
studio and processed in R (version 3.1.1) [21] using the
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lumi package [22] and custom in-house pre-processing
scripts (GitHub, http://bit.ly/1vjyKNo). Briefly, raw
expression data was subject to a model based back-
ground correction for bead array [23]. This used
negative bead expression levels to correct for back-
ground noise. The data was then log base 2 transformed
and robust spline normalized in lumi [22]. Outlying
samples were iteratively identified using fundamental
network concepts and removed, following the meth-
ods described by Oldham et al. [24]. To reduce any
batch effects we adjusted for technical categorical
variables using ComBat [25]. Continuous technical
artifacts were accounted for by taking the first prin-
cipal component across housekeeping and undetected
probes and regressing this against technical variables.
Variables significantly associated with the first princi-
pal component were then regressed against expression
for each probe, and the mean adjusted residuals taken
forward for all further analyses. Finally, the data was
reduced to a subset of probes that could be reliably
detected in 80% of samples in at least one diagnos-
tic group. Finally, subjects were excluded where there
were discrepancies between the recorded sex and sex
determined by the XIST (ILMN 1764573), USP9Y
(ILMN 2056795) and EIF1AY (ILMN 1755537 and
ILMN 2228976) X- and Y-linked genes.
Demographic data for the ANM and DCR subjects
was extracted using CohortExplorer [26].
Pathway level analysis of gene expression
(PLAGE)
Gene level expression data were condensed to sam-
ple wise, pathway level scores using PLAGE [14].
PLAGE groups genes into pathways defined by the
Broad Institute Collection of Curated Pathways [27]
and outputs a score, per sample, for each of these sets.
We restricted PLAGE to only include pathways with
between 10 and 500 genes. The generation of PLAGE
scores was implemented through R package ‘GSVA’
and is detailed in Supplementary Methods, section 1
[13].
Data analysis
Clinical diagnosis (AD versus non-demented elderly
control) classification models were built using batch
1 gene expression data. Variable selection was per-
formed using recursive feature elimination (RFE) and
the creation of a tolerance set using the ‘pickSizeTol-
erance’ function in R. This function finds a smaller set
of variables while maintaining model accuracy [28].
Three Random Forest (RF) models were built, the first
Table 1
Population demographics
AD Control p-value
Batch 1
n 100 107
Sex (% female) 69 58.9 0.149
APOE status (% of APOE 4 positive) 57 32.7 <0.001
APOE 4 load (% with loads 0; 1; 2) 43; 40; 17 67.3; 29; 3.7 <0.001
Median age [IQR] (years) 76 [10] 73 [9] <0.001
Median MMSE score [IQR] 22 [7.25] 29 [1] <0.001
Median years in fulltime education [IQR] 7 [5] 11 [8] <0.001
Sample collection site 0.011
(% from KPO; LDZ; LND; 32; 15; 7; 21.5; 13.1; 21.5;
PRG; THS; TLS) 26; 12; 8 21.5; 6.5; 15.9
Batch 2
n 118 118
Sex (% female) 63.6 61.9 0.893
APOE status (% of APOE 4 positive) 52.5 24.6 <0.001
APOE 4 load (% with loads 0; 1; 2) 47.5; 39.8; 12.7 75.4; 20.3; 4.2 <0.001
Median age [IQR] (years) 78 [9] 74 [8] 0.001
Median MMSE score [IQR] 21 [8] 29 [2] <0.001
Median years in fulltime education [IQR] 9 [7] 11 [5] 0.001
Sample collection site 0.002
(% from KPO; LDZ; LND; 10.2; 18.6; 35.6; 17.8; 7.6; 51.7;
PRG; THS; TLS) 19.5; 10.2; 5.9 17.8; 3.4; 1.7
Individuals were positive for APOE 4 if at least one APOE 4 allele was seen in their genotype. APOE 4 load was the number of alleles
seen in a subjects genotype. Kruskal Wallis Chi-Squared was used to test between cases and controls for continuous data. Fishers exact was
used to test between cases and controls for categorical data. KPO, Kuopio; LDZ, Lodz; LND, London; PRG, Perugia; THS, Thessaloniki; TLS,
Toulouse.
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of which was a model based on demographic data
alone (demographic model) [29]. The demographic
variables included were those that were significant
in the batch 1 population: sample collection site,
age, years in full time education, and APOE status
(defined as the presence of any number of 4 alleles)
(Table 1). Two further models were built based on these
demographic variables and gene level data (gene
model) or PLAGE scores (pathway model). The pur-
pose of the demographic model is to provide a
comparator for the gene and pathway models. If mod-
els that include blood expression information (as well
as demographics) are no more informative than demo-
graphic variables alone there is no benefit in including
this information. All model building was performed
in the statistical software R (Version 3.1.1) using the
‘caret’ package [28].
Each model was used to predict the diagnostic sta-
tus of subjects in batch 2. Model statistics including
accuracy, sensitivity, and specificity were generated
and compared between the demographic model, gene
model, and pathway model. Receiver Operator Curve
(ROC) analysis was also performed in batch 2 data
using R packages ROCR and pROC [30, 31].
Full details of model building are provided in Sup-
plementary Methods section 2.
Additionally, variable importance (determined as
the change in Gini index) was examined in the pathway
model by permutation testing. The idea of permutation
testing is to break the association between outcome
(in this case diagnosis) and predictor variables. When
the model is re-built based on this permuted data any
significant association is spurious. Therefore, by com-
paring the true variable importance of a pathway to the
variable importances that arise by chance in the per-
muted data we can assess how significant our result
is. To achieve this here we used 1000 permutations of
the demographic variables (including diagnosis) and
for each permutation built a RF model. The impor-
tance measures of each pathway were then compared
to that of the original model to generate an empirical
p-value. A p-value of less than 0.05 was considered
significant.
The validity of the pathways selected in the pathway
model was also investigated in a similar way. A random
set of pathways (of the same size as the final pathway
model) were selected, and used to build a RF model.
The fact that this set is random breaks the association
between predictor variables and outcome. This process
was repeated 1000 times and the accuracies across all
models compared to the accuracy of the true model to
create an empirical p-value.
RESULTS
Cohort demographics
Table 1 gives an overview of the demographics of
subjects included in the two batches of gene expression
data.
Data pre-processing
As a result of pre-processing 12 samples in batch
1 and 49 samples in batch 2 failed quality control
(QC) and were removed. The majority of these samples
failed QC as they were identified as outliers. Addition-
ally, some samples were removed because the sex of
the individual recorded in the clinical database did not
match the biological sample (2 samples in batch 1 and
7 in batch 2).
Samples from 19 subjects were present in both batch
1 and batch 2. Samples from 14 of these individuals
passed QC in both batches; only data from batch 1 was
used and the other was discarded. Correlation between
the two batches was at least 0.9 for all individuals (Sup-
plementary Figure 3). Batch 2 gene expression data
contains subjects from the DCR whereas batch 1 does
not. This study used the same protocols, staff, and facil-
ities as the London sample collection site within ANM.
Principal components analysis (PCA) was performed
across the batch 2 gene expression data from DCR and
ANM subjects from London. The first three principal
components (accounting for >40% of variation) were
linearly regressed against the study the individual was
enrolled in (DCR or London ANM) and found to be
non-significant. Therefore, it was deemed appropriate
to group DCR subjects with London ANM, allowing
the model trained in batch 1 data to be simply applied
to batch 2 data.
After data processing only subjects with either an
AD diagnosis at all visits or control status at all visits
were analyzed further: 207 subjects in batch 1 and 236
in batch 2.
Only gene probes that mapped between the version
3 and version 4 chips used to generate batches 1 and
2, respectively, were used for analysis (5212 probes).
The Broad Institute Collection of Curated Pathways
matched these probes to 834 pathways [27].
Data analysis
Demographic model
The following demographic variables were associ-
ated with case/control status in our cohorts (Table 1):
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Table 2
Random Forest model results in independent test data
Model Accuracy [95% CI] Sensitivity Specificity AUC ROC
Demographic model 0.686 [0.623; 0.745] 0.534 0.839 0.771
Demographic model (no samples collection site) 0.674 [0.610; 0.733] 0.678 0.669 0.761
Pathway model 0.657 [0.592; 0.717] 0.610 0.703 0.729
Gene model 0.657 [0.592; 0.717] 0.568 0.746 0.724
CI, Confidence interval; AUC ROC, Areas under the receiver operating curve.
Fig. 2. ROC curves for Random Forest models in independent test
data. ROC, Receiver Operating Characteristic; AUC, Area under the
curve.
age, sex, APOE status, years in full time education, and
sample collection site. These variables were therefore
used in multivariate modeling using RFE. The optimal
cross-validated accuracy was found when including
all variables; calculation of a tolerance set excluded
the variable representing the Lodz sample collection
site. Variable importance scores showed age as the
most important covariate followed by years in full time
education and then APOE status and sample collection
site. In batch 2 test data the model achieved an accuracy
of 0.69, sensitivity of 0.53 and specificity of 0.84.
The area under the ROC curve was 0.77 (see Table 2
and Fig. 2).
Additionally, a model that did not contain the sam-
ple collection site was built. The aim was to create
a model based on demographics that would be avail-
able to clinicians. This model had a slightly decreased
accuracy in comparison to the demographic model but
outperformed the pathway model and gene model in
accuracy, sensitivity and area under the ROC curve
at 0.67, 0.68 and 0.76, respectively. Interestingly, the
specificity of the model was lower than all others at
0.67 (Table 2).
Gene model
The top 5% of variables from the bootstrapped
variable importance calculations (261 variables) were
carried forward to the RFE model building. The opti-
mal cross-validated accuracy from RFE in the gene
model was found for all of the 261 variables; cal-
culation of a tolerance set reduced this set to only
Table 3
Genes in gene model with variable importance scores
Gene (Illumina ID) Variable importance Gene symbol Entrez ID Gene name
ILMN 2189936 11.9 RPL36AL 6166 Ribosomal protein L36a-like
ILMN 2189933 10.8 RPL36AL 6166 Ribosomal protein L36a-like
ILMN 2097421 10.5 MRPL51 51258 Mitochondrial ribosomal protein L51
ILMN 2237746 10.4 ING3 54556 Inhibitor of growth family, member 3
ILMN 1695645 9.2 CETN2 1069 Centrin, EF-hand protein, 2
ILMN 1784286 7.9 NDUFA1 4694 NADH dehydrogenase (ubiquinone)
1 alpha subcomplex
ILMN 1652073 7.0 LOC653658 653658 Ribosomal protein S23 pseudogene 8
ILMN 1716053 7.0 AK2 204 Adenylate kinase 2
ILMN 1732328 6.5 LOC646200 646200
ILMN 1776104 5.9 NDUFS5 4725 NADH dehydrogenase (ubiquinone)
Fe-S protein 5
ILMN 1753892 5.8 LOC654121 654121
ILMN 1745343 5.4 ZMAT2 153527 Zinc finger, matrin-type 2
ILMN 2048326 4.7 RPS27A 6233 Ribosomal protein S27a
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Fig. 3. Percentage overlap of genes belonging to pathways selected for the Random Forest pathway model.
Table 4
Pathways in pathway model with variable importance scores
Pathway Abbreviation Number of genes in pathway Variable importance
KEGG HOMOLOGOUS RECOMBINATION RECOMB 28 13.6∗
BIOCARTA MCALPAIN PATHWAY MCALPAIN 25 7.8∗
REACTOME APC C CDC20 MEDIATED APC 26 7.5
DEGRADATION OF CYCLIN B
REACTOME TGF BETA RECEPTOR SIGNALING IN TGF 16 7.2
EMT EPITHELIAL TO MESENCHYMAL TRANSITION
REACTOME P75NTR SIGNALS VIA NFKB P75NTR 14 6.9
BIOCARTA UCALPAIN PATHWAY UCALPAIN 18 6.8
REACTOME RNA POL III TRANSCRIPTION RNA POL 33 6.4
BIOCARTA NKT PATHWAY NKT 29 6.0
KEGG NUCLEOTIDE EXCISION REPAIR NUCLEOTIDE 44 5.9
REACTOME IRON UPTAKE AND TRANSPORT IRON 36 5.3
BIOCARTA CCR5 PATHWAY CCR5 20 5.3
KEGG ECM RECEPTOR INTERACTION ECM 84 5.0
REACTOME SIGNALING BY CONSTITUTIVELY ACTIVE EGFR EGFR 18 5.0
REACTOME RESPIRATORY ELECTRON TRANSPORT ATP RESPIRATORY 98 4.4
SYNTHESIS BY CHEMIOSMOTIC COUPLING AND
HEAT PRODUCTION BY UNCOUPLING PROTEINS
∗Nominally significant in permutation testing (p < 0.05).
13, excluding all demographic variables. For a list of
genes, see Table 3.
In batch 2 test data, the gene model accuracy was
lower than that of the demographic model and equal
to the pathway model. The sensitivity, specificity, and
area under the ROC curve of the gene model lay
between the demographic and pathway models at 0.59,
0.75, and 0.72, respectively. (see Table 2 and Fig. 2).
Note that the pathway model showed higher sensitiv-
ity while specificity and AUC ROC were higher in the
demographic model.
Pathway model
The top 5% of variables from the bootstrapped
variable importance calculations (42 variables) were
carried forward to the RFE model building. The opti-
mal cross-validated accuracy from RFE in the pathway
model was found for 40 of the variables; calculation of
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a tolerance set reduced this set to only 16 variables
(Table 4): 14 pathways, age, and years in full time
education.
Permutation tests of variable importance were per-
formed to assess the size of effect relative to that
observed under the null hypothesis of no association.
Of the 14 pathways, two achieved nominal significance
with a p-value <0.05 and are indicated with a ∗ in
Table 4 (Supplementary Figure 5).
Additionally, we compared the model accuracy of
1000 models comprising 16 random variables from
the pathways, age, sex, APOE status, and years in full
time education. This yielded a p-value of 0.082 indicat-
ing that, statistically, the final model does not perform
significantly better than a model of random pathways
(Supplementary Figure 4).
In batch 2 test data, the model accuracy was lower
than that of the demographic model at 0.66, however,
the sensitivity was higher at 0.61. Both specificity
and area under the ROC curve were lower than the
demographic model at 0.70 and 0.73, respectively (see
Table 2 and Fig. 2).
There is minimal overlap in genes between the dif-
ferent pathways included in the final pathway model.
This is illustrated by the sparse percentage overlap
map shown in Fig. 3 and supports the idea that each
pathway is contributing an independent signal to the
model. Of the 13 genes included in the gene model,
only four of them (ILMN 1776104, ILMN 1784286,
ILMN 1695645, and ILMN 2048326) appear in any of
the pathways in the pathway model.
Misclassiﬁcation
We discovered that 22% of controls used in the
training data had reported memory complaints deemed
not serious enough to reflect a change in diagno-
sis. By studying misclassification rates split by AD
subjects, control subjects, and control subjects with
memory complaints, we see that the most well classi-
fied group in the gene model was those subjects with
memory complaints whereas in the pathway model it
was control subjects (see Supplementary Figure 6). We
also demonstrated that time since disease onset is not
related to misclassification of AD subjects and con-
trol subjects with memory complaints in the test data
(Supplementary Figure 7).
DISCUSSION
In this study we investigated whether AD cases
could be differentiated from control subjects using
gene expression data analyzed at the pathway level.
We were particularly interested in confirming whether
pathway level information created a more robust pre-
dictor of case/control status than expression data
at the gene level as recent reviews of AD stud-
ies have suggested [11]. Our results, using subjects
from the ANM and DCR cohorts, show similar
model performance in a pathway model compared
to a gene and demographic only model. In this
study, we do not find improved prediction of AD
diagnosis using pathway level information using the
PLAGE method to calculate pathway scores. How-
ever, the robustness of pathway based approaches for
AD biomarker discovery should be tested in other
gene expression data from different populations and
platforms.
The fourteen pathways included in the final pathway
model focused around DNA repair, immune response,
and regulation of cellular activities. Of particular inter-
est to AD, two pathways containing genes from the
calpain gene family were included in the final fourteen
pathways. It is thought that amyloid peptides inter-
fere with calpain activity leading to deregulation of
the CDK5 gene and in turn hyperphosphorylation of
the tau protein. This promotes the death of neurons
[27]. It is encouraging that we have seen relevant path-
ways in our final pathwaymodel. Overall, the pathways
are similar to those identified by Lunnon et al. who
studied overall pathway differences using an identical
raw dataset that was processed differently [9]. As we
would expect, 12 out of 13 of the genes in the final
gene model were present in the genes used for mod-
eling by Lunnon et al. The data had been processed
slightly differently emphasizing that these signals
are robust to alterations in processing and modeling
methods.
RF models are commonly used in biomarker studies
[9, 32, 33]. However, it has been shown that they exhibit
variable selection bias being more likely to select con-
tinuous variables or those with many categories [34].
Additionally, the presence of correlated predictors (as
is common in gene expression studies) can add further
bias [35]. Strobl et al. aimed to address these issues
with an ensemble-learning algorithm based on condi-
tional inference trees; Conditional RF (CRF) models
[36, 37]. We attempted to use this methodology in the
present study. We hypothesized that the creation of an
unbiased predictor may highlight different pathways
and genes to those previously discovered, potentially
allowing greater predictive ability. However, the pro-
cess of creating a CRF model was computationally
expensive even when using high performance com-
N. Voyle et al. / Pathway analysis of gene expression for AD diagnosis 667
puting resources. Model building considering the 834
pathways and 5,212 genes was consequently infea-
sible. Work to improve the efficiency of this method
would be computationally beneficial and would allow
the use of alternative variable importance measures.
Measures such as mean decrease in accuracy and
conditional mean decrease in accuracy would be an
improvement over biased variable importance mea-
sures such as the Gini index, which was used in this
study.
This study used the Broad institute collection of
curated pathways to generate the pathway model and
excluded less well-curated gene sets. This method was
chosen due to its performance in a comparison study
[15] and due to ease of application through the GSVA
R package. It may be beneficial, although potentially
computationally costly, to create pathway level scores
that also reflect pathway topology and thus add further
detail to the model. Such methods have been created
by Pyatnitskiy et al. [38] building on the work of oth-
ers [15, 39]. The method detailed by Pyatnitskiy et
al. does not depend on predefined gene sets as used
in this analysis. However, it is also unable to control
the number of genes in a pathway; a potential bene-
fit of using PLAGE. A further limitation of existing
pathway approaches is that they often ignore informa-
tion on the direction of change for each gene within a
pathway. This would be an interesting area for further
method development.
The creation of a demographic model that excluded
sample collection site led to a drop in accuracy.
Although RNA extraction and analysis were performed
at one site the blood collection may vary by loca-
tion. We aimed to correct for batch effects occurring
in extraction and analysis in the pre-processing. This
highlights that although sample collection sites within
multi-center studies are following the same protocols
major technical differences can still arise and remain
after QC steps including batch correction. As much as
possible, these differences should be quantified dur-
ing extraction. Standardization for future biomarker
development will aid this. It is possible that the sam-
ple collection site effect we see is driven by genetic
differences between sites for some genes (expression
quantitative trait loci). For a biomarker to have clinical
utility it should be robust to such differences. How-
ever, in early exploratory work we are more likely to
find results of interest if technical data artifacts are not
creating a barrier.
The models created in this study all achieved an
accuracy of approximately 70% with the pathway
model having test sensitivity and specificity results of
greater than 60%. The pathway model and gene model
did not outperform a model of demographics alone.
Any potential increase in concordance from the novel
pathway level approach used here has not lead to a
greater predictive ability in these datasets. However,
we have only tested one method for creating pathway
level scores. Further, we have been able to benchmark
pathways against genes in datasets that had been exten-
sively harmonized. It is reassuring to see that pathways
perform similarly to genes and further work is now
needed to see if pathway concordance is more eas-
ily detected using other methodological approaches
and in data generated by independent groups and
platforms.
Furthermore, we found that the heterogeneity of
control subjects may be leading to reduced predictive
accuracy and suggest that the use of an endophenotype
may be beneficial in future work.
CONCLUSIONS
We have used subjects from the ANM and DCR
studies to investigate case/control classification using
gene and pathway level expression data. We hypoth-
esized that a model built on pathway level data may
be more robust than a gene level model and con-
sequently perform better in test data. However, a
pathway level model built using scores and a gene
level model performed similarly to each other and to a
model based on demographic information only. Further
work should focus on the use of alternative methods
for creating pathway level scores, in particular those
that incorporate pathway topology, and the use of an
endophenotype based approach.
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